$TENX Cantor Fitzgerald Reiterates rating and $35 Price Target
Cantor Fitzgerald reiterates overweight rating with a $35 price target (1,695% upside from current $1.95), supported by positive HELP trial data showing safety, efficacy in reducing NT-proBNP by 49%, and a planned enriched LEVEL-2 trial. Insider buying from expert bio investor Dr. Schneeberger and strong analyst support suggest conviction in the biotech's levosimendan program.